Lin C Lin

US Patent:

20120301474, Nov 29, 2012

Filed:

May 11, 2012

Appl. No.:

13/470177

Inventors:

Brad J. Spellberg - Rancho Palos Verdes CA, US
Lin Lin - Rancho Palos Verdes CA, US
Ashraf Ibrahim - Irvine CA, US
Guanpingsheng Luo - Torrance CA, US

Assignee:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA

International Classification:

A61K 39/02
C07K 7/08
C07K 7/06
C07K 5/08
A61P 37/04
C12N 15/63
C07K 16/12
A61K 39/395
A61P 31/04
C07K 14/21
C12N 15/31

US Classification:

4241391, 4242341, 530350, 530326, 530329, 530327, 530324, 530331, 4241901, 536 237, 4353201, 5303879

Abstract:

The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against infection. The compositions and methods of the invention are useful for preventing or treating infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) infections.

US Patent:

20130202616, Aug 8, 2013

Filed:

Jan 24, 2013

Appl. No.:

13/749499

Inventors:

Brad J. Spellberg - Rancho Palos Verdes CA, US
Lin Lin - Rancho Palos Verdes CA, US

Assignee:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA

International Classification:

C12N 9/86
C07K 16/40

US Classification:

4241581, 4242341, 4241781, 5303917, 4242591

Abstract:

The present invention provides vaccine and pharmaceutical compositions for treating or preventing bacterial inventions. The vaccine compositions of the invention include a carbapenemase such as a serine carbapenemase, a metallo-β-lactamase or an immunogenic fragment thereof. The pharmaceutical compositions include an anti-carbapenemase antibody or fragment thereof. Also provided are methods for treating and preventing a bacterial infection using the vaccine and pharmaceutical compositions of the invention. The invention further provides antibody conjugates that include an antibody or fragment thereof conjugated to a siderophore or an analog thereof.

US Patent:

20130310307, Nov 21, 2013

Filed:

Mar 13, 2013

Appl. No.:

13/801324

Inventors:

Lin LIN - Rancho Palos Verdes CA, US

Assignee:

LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER - TORRANCE CA

International Classification:

A61K 38/17

US Classification:

514 27, 514 23, 514 28, 514 33, 514 31, 514 34

Abstract:

The invention provides a method of killing an infectious microbe by administering an effective amount of transferrin to an individual having a microbial infection, wherein the transferrin has microbicidal activity, thereby reducing survival of the infectious microbe in the individual. The invention also provides a method of prophylactically treating an individual to decrease the likelihood of contracting a microbial infection, comprising administering an effective amount of transferrin to an individual, wherein the transferrin has microbicidal activity, thereby decreasing the likelihood that the individual will contract a microbial infection. The invention still further provides a method of treating septicemia by administering an effective amount of transferrin to an individual in need thereof, thereby treating the individual.

US Patent:

20150079116, Mar 19, 2015

Filed:

Apr 11, 2013

Appl. No.:

14/391814

Inventors:

- Oakland CA, US
Lin Lin - Los Angeles CA, US

International Classification:

C12Q 1/68
G01N 33/68

US Classification:

4241831, 506 9, 51426337, 514352, 514567, 514169, 5142632, 5142633, 514249, 514 205, 514291, 506 16, 514398, 51425308, 506 18

Abstract:

NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.

US Patent:

20140335092, Nov 13, 2014

Filed:

May 15, 2014

Appl. No.:

14/279223

Inventors:

- Torrance CA, US
Lin LIN - Rancho Palos Verdes CA, US
Ashraf IBRAHIM - Irvine CA, US
Guanpingsheng LUO - Torrance CA, US

Assignee:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA

International Classification:

C07K 14/22
C07K 16/12

US Classification:

4241391, 5303879, 4241901, 530350, 536 237, 4353201, 530326, 530327

Abstract:

The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against infection. The compositions and methods of the invention are useful for preventing or treating infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) infections.